Martin Cannon
Concepts (288)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Dendritic Cells | 26 | 2023 | 142 | 3.980 |
Why?
| Ovarian Neoplasms | 23 | 2023 | 472 | 3.890 |
Why?
| Cancer Vaccines | 13 | 2020 | 103 | 3.120 |
Why?
| Immunotherapy | 12 | 2019 | 263 | 2.020 |
Why?
| Th17 Cells | 3 | 2020 | 26 | 1.610 |
Why?
| Antigens, Neoplasm | 11 | 2019 | 170 | 1.410 |
Why?
| CD4-Positive T-Lymphocytes | 7 | 2023 | 180 | 1.120 |
Why?
| Uterine Cervical Neoplasms | 12 | 2011 | 276 | 0.980 |
Why?
| Oncogene Proteins, Viral | 7 | 2011 | 57 | 0.870 |
Why?
| Neoplasm Recurrence, Local | 3 | 2020 | 644 | 0.810 |
Why?
| T-Lymphocytes, Regulatory | 6 | 2011 | 85 | 0.780 |
Why?
| T-Lymphocytes, Cytotoxic | 12 | 2013 | 72 | 0.750 |
Why?
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 3 | 2014 | 17 | 0.710 |
Why?
| Lymphocytes, Tumor-Infiltrating | 4 | 2019 | 74 | 0.650 |
Why?
| CD8-Positive T-Lymphocytes | 10 | 2023 | 116 | 0.600 |
Why?
| Neoplasms | 4 | 2019 | 1316 | 0.590 |
Why?
| Interleukin-17 | 2 | 2020 | 38 | 0.580 |
Why?
| DNA-Binding Proteins | 5 | 2007 | 462 | 0.570 |
Why?
| Antibodies, Monoclonal | 5 | 2019 | 562 | 0.560 |
Why?
| p38 Mitogen-Activated Protein Kinases | 2 | 2014 | 99 | 0.550 |
Why?
| Ascites | 1 | 2014 | 28 | 0.490 |
Why?
| Immunologic Surveillance | 2 | 2011 | 14 | 0.470 |
Why?
| T-Lymphocytes | 5 | 2017 | 373 | 0.470 |
Why?
| Carcinoma | 2 | 2017 | 153 | 0.420 |
Why?
| Signal Transduction | 3 | 2017 | 1753 | 0.420 |
Why?
| Female | 41 | 2023 | 28441 | 0.420 |
Why?
| Cytokines | 3 | 2014 | 676 | 0.410 |
Why?
| T-Lymphocytes, Helper-Inducer | 2 | 2011 | 46 | 0.410 |
Why?
| Immunotherapy, Active | 1 | 2011 | 8 | 0.410 |
Why?
| Serine Endopeptidases | 3 | 2009 | 57 | 0.400 |
Why?
| Cytotoxicity, Immunologic | 7 | 2011 | 62 | 0.400 |
Why?
| Humans | 51 | 2023 | 54284 | 0.360 |
Why?
| Immunotherapy, Adoptive | 3 | 2005 | 134 | 0.350 |
Why?
| Adoptive Transfer | 1 | 2009 | 38 | 0.350 |
Why?
| Interferon-gamma | 7 | 2020 | 195 | 0.330 |
Why?
| Epitopes, T-Lymphocyte | 3 | 2008 | 33 | 0.320 |
Why?
| Lymphocyte Activation | 3 | 2005 | 197 | 0.290 |
Why?
| Adjuvants, Immunologic | 3 | 2011 | 61 | 0.290 |
Why?
| Herpesvirus 4, Human | 2 | 2005 | 38 | 0.290 |
Why?
| Papillomavirus Vaccines | 1 | 2007 | 68 | 0.290 |
Why?
| Immunodominant Epitopes | 2 | 2008 | 12 | 0.290 |
Why?
| Dependovirus | 3 | 2011 | 102 | 0.250 |
Why?
| HLA-A2 Antigen | 3 | 2009 | 12 | 0.240 |
Why?
| Animals | 15 | 2023 | 14385 | 0.240 |
Why?
| Cell Line, Tumor | 12 | 2017 | 1550 | 0.240 |
Why?
| Cell Transformation, Viral | 1 | 2003 | 27 | 0.230 |
Why?
| Cell Line, Transformed | 1 | 2003 | 88 | 0.230 |
Why?
| Poxviridae Infections | 1 | 2022 | 4 | 0.220 |
Why?
| Poxviridae | 1 | 2022 | 6 | 0.220 |
Why?
| Myxoma virus | 1 | 2022 | 14 | 0.220 |
Why?
| Interferon Type I | 1 | 2022 | 30 | 0.220 |
Why?
| Cystadenocarcinoma, Serous | 5 | 2009 | 74 | 0.210 |
Why?
| Vaccination | 4 | 2010 | 294 | 0.210 |
Why?
| Papillomavirus E7 Proteins | 5 | 2011 | 33 | 0.210 |
Why?
| Receptor, erbB-2 | 4 | 2008 | 79 | 0.210 |
Why?
| Disease-Free Survival | 2 | 2020 | 485 | 0.210 |
Why?
| Genes, MHC Class I | 3 | 2008 | 13 | 0.200 |
Why?
| Injections, Intradermal | 1 | 2020 | 15 | 0.190 |
Why?
| Testis | 2 | 2011 | 65 | 0.190 |
Why?
| Immunity, Humoral | 1 | 2020 | 25 | 0.190 |
Why?
| Coculture Techniques | 3 | 2014 | 160 | 0.190 |
Why?
| Membrane Proteins | 4 | 2011 | 389 | 0.190 |
Why?
| Macrophages | 4 | 2022 | 405 | 0.190 |
Why?
| Folate Receptor 1 | 1 | 2020 | 24 | 0.190 |
Why?
| Cell Movement | 2 | 2019 | 271 | 0.180 |
Why?
| Enzyme-Linked Immunosorbent Assay | 2 | 2013 | 314 | 0.180 |
Why?
| Carcinoma, Lewis Lung | 1 | 2019 | 11 | 0.180 |
Why?
| Self Tolerance | 1 | 2019 | 1 | 0.170 |
Why?
| Costimulatory and Inhibitory T-Cell Receptors | 1 | 2019 | 1 | 0.170 |
Why?
| Melanoma, Experimental | 1 | 2019 | 49 | 0.170 |
Why?
| Repressor Proteins | 3 | 2011 | 165 | 0.170 |
Why?
| Flow Cytometry | 7 | 2013 | 546 | 0.170 |
Why?
| Transplantation, Autologous | 1 | 2020 | 476 | 0.170 |
Why?
| B-Lymphocytes | 4 | 2017 | 176 | 0.170 |
Why?
| Cytotoxicity Tests, Immunologic | 4 | 2005 | 31 | 0.160 |
Why?
| Aged | 11 | 2020 | 10054 | 0.160 |
Why?
| N-Acetylglucosaminyltransferases | 1 | 2017 | 19 | 0.150 |
Why?
| Cells, Cultured | 6 | 2014 | 1737 | 0.150 |
Why?
| Programmed Cell Death 1 Receptor | 1 | 2017 | 40 | 0.150 |
Why?
| Receptors, Notch | 1 | 2017 | 28 | 0.150 |
Why?
| HLA Antigens | 4 | 2006 | 55 | 0.150 |
Why?
| Interleukin-10 | 1 | 2017 | 107 | 0.150 |
Why?
| Human Umbilical Vein Endothelial Cells | 2 | 2014 | 95 | 0.150 |
Why?
| Mice | 8 | 2023 | 6413 | 0.150 |
Why?
| Middle Aged | 15 | 2020 | 13088 | 0.140 |
Why?
| Neoplastic Stem Cells | 1 | 2017 | 103 | 0.140 |
Why?
| Carcinoma, Papillary | 3 | 2005 | 65 | 0.140 |
Why?
| Poliovirus Vaccine, Oral | 2 | 2005 | 5 | 0.130 |
Why?
| Poliovirus | 2 | 2005 | 9 | 0.130 |
Why?
| Genetic Vectors | 3 | 2011 | 139 | 0.130 |
Why?
| Clinical Trials, Phase I as Topic | 1 | 2015 | 30 | 0.130 |
Why?
| Antigen Presentation | 5 | 2009 | 28 | 0.130 |
Why?
| Neoplasm Proteins | 1 | 2017 | 359 | 0.130 |
Why?
| Galectin 3 | 1 | 2014 | 15 | 0.130 |
Why?
| Kallikreins | 2 | 2005 | 22 | 0.130 |
Why?
| Adenocarcinoma | 3 | 2004 | 428 | 0.130 |
Why?
| Adult | 14 | 2011 | 14207 | 0.120 |
Why?
| Neoplasm Invasiveness | 3 | 2017 | 295 | 0.120 |
Why?
| Cystadenocarcinoma, Papillary | 2 | 2005 | 15 | 0.120 |
Why?
| Histocompatibility Antigens Class I | 2 | 2005 | 52 | 0.120 |
Why?
| Endometrial Neoplasms | 2 | 2005 | 144 | 0.120 |
Why?
| Peptide Fragments | 4 | 2009 | 242 | 0.120 |
Why?
| Papillomavirus Infections | 3 | 2011 | 163 | 0.120 |
Why?
| Uterine Neoplasms | 2 | 2005 | 63 | 0.120 |
Why?
| Intracellular Signaling Peptides and Proteins | 2 | 2022 | 151 | 0.110 |
Why?
| Mice, Inbred C57BL | 3 | 2017 | 1999 | 0.110 |
Why?
| Mutation | 1 | 2019 | 1501 | 0.100 |
Why?
| Lymphocytes | 1 | 2013 | 168 | 0.100 |
Why?
| V-Set Domain-Containing T-Cell Activation Inhibitor 1 | 1 | 2011 | 4 | 0.100 |
Why?
| Antigens, Viral | 3 | 2007 | 58 | 0.100 |
Why?
| rho GTP-Binding Proteins | 1 | 2011 | 6 | 0.100 |
Why?
| Clonal Anergy | 1 | 2011 | 14 | 0.100 |
Why?
| Drug Resistance, Neoplasm | 5 | 2017 | 309 | 0.100 |
Why?
| A Kinase Anchor Proteins | 1 | 2011 | 1 | 0.100 |
Why?
| Calmodulin-Binding Proteins | 1 | 2011 | 9 | 0.100 |
Why?
| Antigen-Presenting Cells | 1 | 2011 | 25 | 0.100 |
Why?
| Antigens, Surface | 1 | 2011 | 55 | 0.100 |
Why?
| Human papillomavirus 16 | 1 | 2011 | 48 | 0.100 |
Why?
| Antineoplastic Agents, Alkylating | 1 | 2011 | 74 | 0.100 |
Why?
| Uterine Cervical Dysplasia | 1 | 2011 | 51 | 0.100 |
Why?
| Immunity, Cellular | 2 | 2008 | 80 | 0.100 |
Why?
| Cyclophosphamide | 1 | 2011 | 172 | 0.100 |
Why?
| Prostate | 1 | 2011 | 117 | 0.090 |
Why?
| Diphosphonates | 1 | 2011 | 96 | 0.090 |
Why?
| Imidazoles | 1 | 2011 | 142 | 0.090 |
Why?
| Papillomaviridae | 3 | 2005 | 107 | 0.090 |
Why?
| Killer Cells, Natural | 3 | 2005 | 107 | 0.090 |
Why?
| Phenotype | 1 | 2013 | 820 | 0.090 |
Why?
| Gene Expression Regulation, Neoplastic | 4 | 2011 | 866 | 0.090 |
Why?
| Neoplasm Staging | 3 | 2007 | 806 | 0.090 |
Why?
| Tumor Microenvironment | 2 | 2023 | 209 | 0.090 |
Why?
| K562 Cells | 2 | 2008 | 47 | 0.090 |
Why?
| Gene Expression Profiling | 2 | 2005 | 1138 | 0.090 |
Why?
| Carrier Proteins | 1 | 2011 | 359 | 0.090 |
Why?
| CA-125 Antigen | 1 | 2008 | 20 | 0.080 |
Why?
| Immediate-Early Proteins | 1 | 2008 | 19 | 0.080 |
Why?
| Cytomegalovirus | 1 | 2008 | 30 | 0.080 |
Why?
| Green Fluorescent Proteins | 1 | 2008 | 110 | 0.080 |
Why?
| Interleukin-4 | 2 | 2005 | 48 | 0.080 |
Why?
| RNA, Messenger | 4 | 2005 | 1202 | 0.080 |
Why?
| Antibody Formation | 1 | 2007 | 69 | 0.080 |
Why?
| Antibodies, Viral | 1 | 2007 | 124 | 0.080 |
Why?
| Prostatic Neoplasms | 1 | 2011 | 415 | 0.070 |
Why?
| RNA Interference | 2 | 2017 | 195 | 0.070 |
Why?
| Ovary | 3 | 2017 | 105 | 0.070 |
Why?
| Amino Acid Sequence | 2 | 2005 | 767 | 0.070 |
Why?
| Molecular Sequence Data | 2 | 2005 | 980 | 0.070 |
Why?
| Oligonucleotide Array Sequence Analysis | 2 | 2005 | 474 | 0.070 |
Why?
| Hypersensitivity, Delayed | 1 | 2005 | 21 | 0.070 |
Why?
| Recombinant Proteins | 1 | 2007 | 569 | 0.070 |
Why?
| Neoplasms, Squamous Cell | 1 | 2005 | 9 | 0.070 |
Why?
| Electroporation | 1 | 2005 | 17 | 0.070 |
Why?
| Enterotoxins | 1 | 2005 | 12 | 0.070 |
Why?
| Monocytes | 2 | 2022 | 156 | 0.070 |
Why?
| Gene Transfer Techniques | 1 | 2005 | 41 | 0.070 |
Why?
| Genes, erbB-2 | 1 | 2005 | 8 | 0.070 |
Why?
| Poliomyelitis | 1 | 2005 | 15 | 0.070 |
Why?
| Breast Neoplasms | 3 | 2003 | 1248 | 0.070 |
Why?
| Interleukin-12 | 1 | 2005 | 37 | 0.070 |
Why?
| Antigens, Heterophile | 1 | 2005 | 2 | 0.070 |
Why?
| Immunologic Memory | 1 | 2005 | 32 | 0.070 |
Why?
| Plasmodium falciparum | 1 | 2005 | 18 | 0.070 |
Why?
| Malaria, Falciparum | 1 | 2005 | 12 | 0.060 |
Why?
| Burkitt Lymphoma | 1 | 2005 | 29 | 0.060 |
Why?
| Cell Line | 4 | 2010 | 1153 | 0.060 |
Why?
| Endemic Diseases | 1 | 2005 | 29 | 0.060 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2008 | 673 | 0.060 |
Why?
| Epstein-Barr Virus Infections | 1 | 2005 | 34 | 0.060 |
Why?
| Gangliosides | 1 | 2004 | 9 | 0.060 |
Why?
| Ascitic Fluid | 1 | 2004 | 13 | 0.060 |
Why?
| Genetic Therapy | 1 | 2005 | 121 | 0.060 |
Why?
| Vaccines, Subunit | 1 | 2004 | 20 | 0.060 |
Why?
| Ovariectomy | 1 | 2004 | 125 | 0.060 |
Why?
| Hysterectomy | 1 | 2004 | 88 | 0.060 |
Why?
| Immunization, Passive | 1 | 2004 | 35 | 0.060 |
Why?
| Proteins | 2 | 2005 | 376 | 0.060 |
Why?
| Interleukin-6 | 1 | 2005 | 315 | 0.060 |
Why?
| Clinical Trials as Topic | 2 | 2007 | 490 | 0.060 |
Why?
| Tumor Necrosis Factor-alpha | 2 | 2019 | 434 | 0.060 |
Why?
| Cell Differentiation | 2 | 2004 | 720 | 0.060 |
Why?
| Virus Latency | 1 | 2003 | 46 | 0.060 |
Why?
| Epithelial Cells | 1 | 2005 | 255 | 0.060 |
Why?
| Protein Binding | 1 | 2005 | 736 | 0.060 |
Why?
| Vaccinia virus | 1 | 2022 | 7 | 0.060 |
Why?
| Host Specificity | 1 | 2022 | 5 | 0.060 |
Why?
| Cell Adhesion Molecules | 1 | 2003 | 87 | 0.060 |
Why?
| Cell Communication | 1 | 2003 | 72 | 0.060 |
Why?
| Nucleotidyltransferases | 1 | 2022 | 15 | 0.050 |
Why?
| Mammals | 1 | 2022 | 57 | 0.050 |
Why?
| Tumor Cells, Cultured | 4 | 2003 | 477 | 0.050 |
Why?
| Xenograft Model Antitumor Assays | 2 | 2017 | 219 | 0.050 |
Why?
| Disease Progression | 2 | 2019 | 913 | 0.050 |
Why?
| Rabbits | 1 | 2022 | 425 | 0.050 |
Why?
| Down-Regulation | 1 | 2003 | 388 | 0.050 |
Why?
| Viral Proteins | 1 | 2022 | 158 | 0.050 |
Why?
| Immunohistochemistry | 4 | 2005 | 1089 | 0.050 |
Why?
| Carcinoma, Squamous Cell | 1 | 2004 | 384 | 0.050 |
Why?
| Transcriptome | 1 | 2022 | 346 | 0.050 |
Why?
| Endothelium | 1 | 2019 | 45 | 0.040 |
Why?
| Intercellular Adhesion Molecule-1 | 1 | 2019 | 75 | 0.040 |
Why?
| Gene Expression | 3 | 2008 | 664 | 0.040 |
Why?
| Injections, Intraperitoneal | 2 | 2010 | 59 | 0.040 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2004 | 1056 | 0.040 |
Why?
| Tissue Banks | 1 | 2017 | 8 | 0.040 |
Why?
| Mice, Inbred NOD | 1 | 2017 | 99 | 0.040 |
Why?
| STAT3 Transcription Factor | 1 | 2017 | 87 | 0.040 |
Why?
| Glycosylation | 1 | 2017 | 112 | 0.040 |
Why?
| Antibodies, Monoclonal, Humanized | 3 | 2004 | 240 | 0.040 |
Why?
| Tumor Burden | 1 | 2017 | 142 | 0.040 |
Why?
| RNA, Small Interfering | 1 | 2017 | 252 | 0.040 |
Why?
| Multiple Myeloma | 1 | 2011 | 3035 | 0.040 |
Why?
| Protein Processing, Post-Translational | 1 | 2017 | 183 | 0.030 |
Why?
| Lung Neoplasms | 1 | 2002 | 642 | 0.030 |
Why?
| Kaplan-Meier Estimate | 1 | 2017 | 514 | 0.030 |
Why?
| Survival Analysis | 2 | 2010 | 735 | 0.030 |
Why?
| Apoptosis | 2 | 2014 | 1300 | 0.030 |
Why?
| Neovascularization, Pathologic | 1 | 2014 | 168 | 0.030 |
Why?
| Anti-Bacterial Agents | 1 | 2019 | 820 | 0.030 |
Why?
| Interleukin-2 | 2 | 2003 | 75 | 0.030 |
Why?
| Vaginal Smears | 1 | 2011 | 31 | 0.030 |
Why?
| Organ Specificity | 1 | 2011 | 126 | 0.020 |
Why?
| Prostate-Specific Antigen | 1 | 2011 | 55 | 0.020 |
Why?
| DNA, Viral | 1 | 2011 | 142 | 0.020 |
Why?
| Major Histocompatibility Complex | 1 | 2010 | 14 | 0.020 |
Why?
| Prognosis | 2 | 2005 | 2118 | 0.020 |
Why?
| Transduction, Genetic | 1 | 2008 | 50 | 0.020 |
Why?
| Fluorescent Antibody Technique | 1 | 2008 | 141 | 0.020 |
Why?
| Leukocytes, Mononuclear | 1 | 2008 | 133 | 0.020 |
Why?
| T-Lymphocyte Subsets | 1 | 2007 | 41 | 0.020 |
Why?
| Alphapapillomavirus | 1 | 2007 | 16 | 0.020 |
Why?
| Models, Immunological | 1 | 2007 | 10 | 0.020 |
Why?
| Immune Tolerance | 1 | 2007 | 104 | 0.020 |
Why?
| Aged, 80 and over | 2 | 2005 | 3431 | 0.020 |
Why?
| HLA-B Antigens | 1 | 2006 | 7 | 0.020 |
Why?
| Clone Cells | 1 | 2006 | 89 | 0.020 |
Why?
| Adolescent | 2 | 2011 | 6897 | 0.020 |
Why?
| Immunity, Innate | 1 | 2007 | 114 | 0.020 |
Why?
| Claudin-3 | 1 | 2005 | 5 | 0.020 |
Why?
| Claudin-4 | 1 | 2005 | 7 | 0.020 |
Why?
| Pore Forming Cytotoxic Proteins | 1 | 2005 | 6 | 0.020 |
Why?
| Perforin | 1 | 2005 | 8 | 0.020 |
Why?
| Mice, Inbred C3H | 1 | 2005 | 82 | 0.020 |
Why?
| Combined Modality Therapy | 1 | 2007 | 692 | 0.020 |
Why?
| Male | 3 | 2011 | 27334 | 0.020 |
Why?
| Protein Sorting Signals | 1 | 2005 | 10 | 0.020 |
Why?
| Protein Engineering | 1 | 2005 | 21 | 0.020 |
Why?
| Mice, SCID | 1 | 2005 | 196 | 0.020 |
Why?
| Histocompatibility Antigens Class II | 1 | 2005 | 43 | 0.020 |
Why?
| Protein Folding | 1 | 2005 | 52 | 0.020 |
Why?
| Species Specificity | 1 | 2005 | 205 | 0.020 |
Why?
| Plasmids | 1 | 2005 | 180 | 0.020 |
Why?
| Peptides | 1 | 2006 | 276 | 0.020 |
Why?
| Epithelium | 1 | 2004 | 68 | 0.020 |
Why?
| Endocytosis | 1 | 2005 | 60 | 0.020 |
Why?
| Carboplatin | 1 | 2004 | 62 | 0.020 |
Why?
| Radiotherapy, Adjuvant | 1 | 2004 | 66 | 0.020 |
Why?
| Receptors, Cell Surface | 1 | 2005 | 130 | 0.020 |
Why?
| Antineoplastic Agents, Hormonal | 1 | 2004 | 49 | 0.020 |
Why?
| Disease Models, Animal | 1 | 2010 | 1639 | 0.020 |
Why?
| Transfection | 1 | 2005 | 399 | 0.020 |
Why?
| Antibody-Dependent Cell Cytotoxicity | 1 | 2003 | 15 | 0.010 |
Why?
| Paclitaxel | 1 | 2004 | 103 | 0.010 |
Why?
| Tumor Stem Cell Assay | 1 | 2003 | 21 | 0.010 |
Why?
| Membrane Glycoproteins | 1 | 2005 | 269 | 0.010 |
Why?
| Polymerase Chain Reaction | 1 | 2005 | 531 | 0.010 |
Why?
| Proportional Hazards Models | 1 | 2005 | 431 | 0.010 |
Why?
| Cervix Uteri | 1 | 2004 | 53 | 0.010 |
Why?
| Swine | 1 | 2005 | 431 | 0.010 |
Why?
| Keratinocytes | 1 | 2004 | 96 | 0.010 |
Why?
| Up-Regulation | 1 | 2005 | 508 | 0.010 |
Why?
| Kinetics | 1 | 2005 | 692 | 0.010 |
Why?
| Receptors, Antigen, T-Cell | 1 | 2003 | 50 | 0.010 |
Why?
| Time Factors | 1 | 2010 | 3213 | 0.010 |
Why?
| Leukocytes | 1 | 2003 | 85 | 0.010 |
Why?
| Cell Culture Techniques | 1 | 2003 | 112 | 0.010 |
Why?
| Doxorubicin | 1 | 2004 | 259 | 0.010 |
Why?
| Cell Death | 1 | 2003 | 223 | 0.010 |
Why?
| Tumor Virus Infections | 1 | 2002 | 43 | 0.010 |
Why?
| Survival Rate | 1 | 2005 | 951 | 0.010 |
Why?
| Antibodies, Monoclonal, Murine-Derived | 1 | 2002 | 55 | 0.010 |
Why?
| Cisplatin | 1 | 2004 | 352 | 0.010 |
Why?
| Fatal Outcome | 1 | 2002 | 225 | 0.010 |
Why?
| Young Adult | 1 | 2011 | 4318 | 0.010 |
Why?
| Cell Division | 1 | 2002 | 330 | 0.010 |
Why?
| Case-Control Studies | 1 | 2004 | 1228 | 0.010 |
Why?
| Prospective Studies | 1 | 2004 | 2604 | 0.010 |
Why?
| Risk Factors | 1 | 2004 | 3935 | 0.010 |
Why?
| Antineoplastic Agents | 1 | 2002 | 1300 | 0.010 |
Why?
|
|
Cannon's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|